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Cytotoxicity of mercury compounds in LLC-PK1, MDCK and human
proximal tubular cells. Six mercury compounds [HgCI2 (MC),
Hg(CH3COO)2 (MA), Hg(N03)2 (MN), C2H5HgSC6H4COONa (EMT),
C6H5HgOCOCH3 (PMA) and CH3CIHg (MMC)] were studied using two
kidney cell lines (MDCK and LLC-PK1), primary cultures of human
proximal tubular cells (hPTC) and nonrenal cell lines (SAOS and Hep
G2). Cell damage was measured with four different tests: neutral red
uptake, mitochondrial dehydrogenase activity (MT'F conversion), thymi-
dine incorporation and protein content. Relative toxicity was established
by the determination of the concentration of test compound inducing a
50% reduction of the parameter considered (EC5O value). Two groups
could be distinguished: PMA, EMT and MMC are one order of magnitude
more toxic than MC, MN and MA. Cellular uptake was measured by the
HPLC-hybrid generation AAS after 24 hours treatment with 1.5 jsM MC,
MMC, PMA or EMT in MDCK cells, revealing Hg concentrations of
42.8 2.5 ng/mg protein for MC, 596.9 87.8 ng/mg protein for MMC,
269.8 75.7 nglmg protein for PMA and of 115.9 25.2 nglmg protein for
EMT. Cytotoxicity was positively correlated with cellular uptake. The
effect of the cellular GSH content on the toxicity of mercury was studied
using the OSH synthesis inhibitor L-buthionine sulfoximine (BSO). In all
cases an enhanced cytotoxicity was observed after BSO treatment. 2-Oxo-
4-thiazolidine carboxylic acid (OTC) was used as a substrate for the GSH
synthesis. Although OTC did not enhance the GSH content, the cytotox-
icity of MC, MN and MA decreased significantly, no changes were
observed for the other mercurials. HPLC-hydrid generation AAS revealed
that OTC is complexed in the growth medium with MC, but not with
EMT, whereas no interactions were observed between BSO and the
mercury compounds. From a toxicological point of view two groups can be
considered: MMC, EMT and PMA are one order of magnitude more toxic
than MC, MA and MN in all cell lines studied, This difference in toxicity
was proportional with the uptake of those compounds. Extracellular
complexation of mercury with OTC is correlated with decreasing cytotox-
icity in the absence of enhanced GSH. GSH inhibition by BSO resulted in
a higher toxicity, within comparable cellular uptake, confirming the
function of GSH in the detoxification of mercury.
Mercury compounds are important environmental pollutants
[1] and have strong nephrotoxic and neurotoxic effects on humans
and animals. Renal toxicity of mercury is related both to its
accumulation in the proximal tubules [2, 3] and its intracellular
binding to functional groups such as sulfydryl, carboxyl and
phosphoryl. Binding results in enzyme inactivation and inhibition
of protein synthesis. The specific action mechanism underlying
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mercury promoted oxidative tissue damage is unknown [4]. Mer-
cury chloride has the potential to induce an autoimmune re-
sponse, more specifically for the kidney of Brown-Norway rats,
with the formation of antiglomerular basement membrane anti-
bodies [5, 6]. Renal and nervous toxicity of mercury chloride has
extensively been studied in rat and mice [7—91 and in a cohort of
workers from different parts of the world exposed in the chloral-
kali industry [10—12]. Cytotoxicity of mercury chloride has already
been studied in a Madin-Darby bovine kidney (MDBK) cell line
[13] and in primary cultures of rabbit proximal tubular cells [14].
Different protection mechanisms against mercury insult have
been described. Some bacteria are resistant to mercury because
they possess a mercuric reductase, which reduces divalent mer-
cury to metallic mercury [15]. An enhanced stress protein synthe-
sis (heat shock protein) could be noted in rat kidney after
mercuric chloride treatment [161. Other protection mechanisms
are the GSH system [17—19] and metallothioneins [20]. Metallo-
thioneins (MT5) are cysteine-rich, metal binding proteins believed
to be involved in metal homeostasis and in the protection of cells
and tissues from the cytotoxic effects of soft heavy-metal ions such
as Zn (II), Cd (II), Cu (II) and Hg (II) [21]. Glutathione (GSH)
plays an important role in the detoxification of potentially toxic
compounds by its conjugation with xenobiotics or their metabo-
lites. This conjugation is catalyzed by the glutathione S-trans-
ferases (GST).
Manipulation of the GSH content is useful for both experimen-
tal [22] and therapeutic purposes, such as the prevention of
paracetamol induced hepatotoxicity by the administration of
N-acetylcysteine, a precursor of GSH [23]. Several approaches
allow depletion of GSH. Treatment with BSO or diethylmaleate
are mostly used [24]; BSO is a specific inhibitor of y-glutamylcys-
teine synthetase, a key enzyme in the biosynthesis of GSH. There
are several ways to enhance the GSH content, such as the
administration of OTC [25], lipoic acid [26], glutathione ester [27]
and glycine [28]. The cellular uptake of GSH itself is rather
inefficient [29].
The aim of this study was to evaluate human proximal tubular
cells (hPTC) and dog and pig kidney epithelial cell lines (MDCK,
LLC-PK1) as models of in vitro nephrotoxicity with several
mercury compounds as toxic substances. The neutral red uptake,
the MTT conversion, the thymidine incorporation and the total
protein determination were used as cytotoxicity tests. Relations
between the cytotoxicity and the mercury uptake were researched,
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The mercury insult was also measured in terms of function of an
altered GSH content using BSO and OTC.
Methods
Cells and cell lines
MDCK, a dog cell line with mainly distal tubular characteristics,
and Hep G2 cells, a hepatoma-derived cell line, were cultured in
Dulbecco's modified Eagle's medium (DMEM) supplemented
with 10% fetal calf serum (FCS, SEBAK GmbH, Aidenbach,
Germany). LLC-PK1 cells (pig kidney proximal tubular cells) were
maintained in Medium 199 containing 5% FCS and SAOS
(osteoblast) cells in Nutrient Mixture Ham's F-12 with 10% FCS.
hPTC cells were obtained after a method developed by Van Der
Biest et al [30]. hPTC cells were grown in MEM Alpha medium
modified according to Gibson-d'Ambrosio et al [31], without
antibiotics and supplemented with 10% FCS. These culture
medium conditions are called "complete medium" further on. All
cells were maintained in a humified 5% CO2 atmosphere at 37°C.
The cells were subcultured using 0.25% trypsin-0.02% EDTA. For
the subculturing of Hep G2 cells 0.25% trypsin without EDTA
was used. To normalize the cytotoxicity tests, cells were counted in
a Burker counting chamber, starting all tests with the same cell
density. Cell culture chemicals were purchased from Life Tech-
nologies (Gibco, Paisley, UK).
Test compounds
HgCl2 (MC, mercury chloride), Hg(N03)2 (MN, mercury ni-
trate), C2H5HgSC6H4COONa (EMT, sodium ethylmercurithiosa-
licylate) and CH3CIHg (MMC, methyl mercury chloride) were
dissolved in the appropriate cell medium containing 1% FCS.
After dissolution in ethanol Hg(CH3COO)2 (MA, mercury ace-
tate) and C6H5HgOCOCH3 (PMA, phenylmercury acetate) were
brought into specific cell medium containing 1% FCS. MC, MN
and MA were purchased from E. Merck (Darmstadt, Germany),
EMT and PMA from Fluka AG (Buchs, Switzerland), and MMC
from K & K Laboratories (ICN Biomedicals, Inc., Cleveland, OH,
USA).
Cytotoxicity assays
Neutral red uptake (NR) and MiT conversion. The cells were
seeded into the wells of a 96-well tissue culture plate: 5 X io cells
in 0.2 ml complete medium per well. After 24 hours the medium
was removed by inverting the multiwell plate. Eight control
cultures received 0.2 ml of fresh medium containing 1% FCS. The
test cultures were treated with 0.2 ml aliquots of different
concentrations of the freshly prepared test compounds in medium
with 1% FCS. Eight wells were used per concentration. After a
further 24 hours, the medium was removed, and the cells were
washed with 0.9% NaCI.
For the neutral red uptake assay [32] the cells were treated at
37°C with 0.2 ml (50 ig/ml) neutral red (Fluka AG, Buchs,
Switzerland) in complete medium. After three hours, the medium
was removed and replaced for 15 seconds by 0.2 ml of a solution
composed of 0.37% formaldehyde (E. Merck) and 1% calcium
chloride. This solution was replaced by 0.2 ml of 1% acetic acid in
50% ethanol and was shaken until a homogeneous color was
obtained. The absorbance was then measured at 540 nm with a
microplate reader (Eurogenetics, Tessenderlo, Belgium). The
mean A540 of the control wells represented 100% viability. The
relative toxicity of the test compounds was established by deter-
mination of the EC5O value for the neutral red uptake, that is, the
concentration of test compound required to induce a 50% inhi-
bition of neutral red uptake.
For the MTT conversion, the cells were treated with 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTF,
Janssen Chimica, Beerse, Belgium). The soluble pale yellow MTT
salt was reduced by mitochondrial succinate dehydrogenase into
an insoluble dark blue formazan product. Only living cells reduced
significant amounts of MTT [33]. MTT was prepared as a stock
solution of 2.5 mg/ml in phosphate buffered saline (PBS), filter-
sterilized and stored in the dark at 4°C. MTT-containing medium
was added to each well in a volume of 0.1 ml (0.25 mg MTT/well).
After a four hour incubation at 37°C, the incubation medium was
aspirated and 0.2 ml DMSO/well was added to solubilize the MiT
formazan product. After mixing, the absorbance was measured at
570 nm. EC5O values for the MTF conversion were determined.
Thymidine incorporation and protein determination. The cells
were seeded into the wells of a 96-well tissue culture plate, 5 X i0
cells in 0.2 ml complete medium per well, four wells per concen-
tration. After 24 hours, the medium was removed by inverting the
multiwell plate. Four control cultures received 0.2 ml of fresh
medium containing 1% FCS. The test cultures were incubated for
24 hours with 0.2 ml aliquots of different concentrations of the
freshly prepared test compounds in medium with 1% FCS. Four
wells were used per concentration. Thereafter, the medium was
removed, and the cells were incubated with 0.2 ml (1 Ci/well)
(3H)-thymidine (Amersham mt., UK) for 24 hours at 37°C in a
5% CO atmosphere. The cells were washed twice with 0.2 ml
PBS/well, and were fixed with 0.2 ml 5% TCA (E. Merck) in
PBS/well at 4°C during 30 minutes. TCA was removed by aspira-
tion. The cells were lysed by incubation with 0.1 M NaOH + 0.1%
Triton X-100 (0.2 mI/well) for 30 minutes at 60°C. The lysates
were diluted 1/2 with PBS. 3H in the lysate was counted with 10 ml
Instagel in a Beckman LS-5000CE scintillation counter. Protein
content was determined by the BCA method (Pierce BCA protein
Assay Reagent, Illinois, USA) with bovine serum albumin (Boer-
hinger) as a standard.
The relative toxicity of the test compounds was expressed by the
EC5O value for thymidine incorporation and protein content,
which is the concentration (in xM) of test compound required to
induce a 50% reduction in thymidine and protein content, respec-
tively.
Determination of the DNA content
MDCK cells were seeded into the wells of a 24-well tissue
culture plate at a density of 3 X io cells/well in 1 ml complete
medium, four wells per concentration. After 24 hours, the me-
dium was aspirated and the cells were treated with MC or EMT in
medium with 1% FCS during 24 hours. Thereafter mercury
containing medium was replaced by complete medium for another
24 hours. Cells were washed twice with 1 ml PBS and lysed during
15 minutes at 37°C with 100 1td ETh (10 mrvi EDTA, 10 mM
Tris-HCI, 100 mrvi NaCI, pH 7.0) with 0.2% SDS. The DNA content
was measured in the lysate (100 1.d, dilution 1/40) after incubation
with 2.4 ml ETN supplemented with 100 ng/ml Hoechst 33258
(Boerhinger) and 5 xg/ml RNAse (Boerhinger) during 15 minutes
at 37°C. Fluorescence was measured at an excitation wavelength
of 360 nm and an emission wavelength of 450 nm. Calf thymus
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DNA (Sigma Chemical Co., St. Louis, MO, USA) was used as the
standard.
Atomic absorption spectrometty (AAS)
MDCK or LLC-PK1 cells were seeded in a culture bottle at a
density of 6.8 X 106 cells per 80 cm2. After 24 hours the cells were
treated during another 24 hours with sublethal mercury concen-
trations of 0.15 to 15 M. The cells were washed twice with 30 ml
Hank's balanced salt solution (HBSS, Life Technologies, Paisley,
UK) and harvested with a policeman in 1 ml bidistilled water.
The intracellular Hg concentration was determined with flame-
less atomic absorption spectrometry by means of the mercury
hydrid technique. Sample preparation was performed using a
method previously developed [34] for the direct determination of
Hg in whole blood. In brief, 20 to 500 jxl sample volume of the cell
suspension was transferred to a plastic container upon which were
added 10 ml of bidistilled water, 250 .d of 30% HNO3, 1 drop
KMNO4 3% wt/vol and five drops of an antifoaming agent.
Samples were determined against a matrix matched calibration
curve. The detection limit of the method was 0.59 xg/liter,
whereas the within and between run CV's were below 7%.
High performance liquid chromatography-hydrid generation AAS
To study possible extracellular interactions between the differ-
ent mercury compounds and BSO or OTC a previously developed
HPLC-ETAAS method [35] was adapted allowing the separation
of ligand and non-ligand bound Hg compounds. Firstly, BSO and
OTC were determined in post-HPLC elution fractions at 220 nm
by UV spectrometry. Then DMEM + 1% FCS with/without 100
LM BSO or 1 mM OTC were incubated with MC or EMT for 24
hours and were subsequently injected into the HPLC system. The
separated fractions were then analyzed for their Hg content with
hydrid generation AAS as described above. Thus, possible co-
elution of MC or EMT with OTC or BSO could be detected.
Alteration of the GSH content
The endogeneous GSH content was reduced with L-buthionine
sulfoximine (BSO, a specific inhibitor of GSH synthesis) or
enhanced with 2-oxo-4-thiazolidine carboxylic acid (OTC, a sub-
strate for GSH synthesis). BSO and OTC were both obtained
from Sigma Chemical Co.
Determination of the GSH content
MDCK and Hep G2 cells were seeded at a density of 4.2 x 106
per petri dish, SAOS and LLC-PK1 cells at a density of 8.4 X 106.
After 24 hours growth, the cells were treated during 24 hours with
complete medium with 0 to 400 LM BSO or 0 to 10 mM OTC.
After 24 hours the medium was replaced by fresh medium with
the same concentration of BSO or OTC for another 24 hours. The
cells were then washed two times with 10 ml HBBS (Life
Technologies, Paisley, UK), harvested and homogenized in 1 ml
100 mM Sørensen phosphate buffer pH 7.4. The proteins were
precipitated with an equal volume of sulfosalicylic acid (SSA, E.
Merck). After centrifugation (3000 X g for 15 mm), the superna-
tant was assayed for GSH following the method of Ellman [36] or
the method of Tietze [37. Cellular proteins were measured by the
Bradford method (Bio-Rad Laboratories GmbH, Munchen, Ger-
many) with bovine serum albumin as a standard.
Determination of the glutathione S-rransferase activity
MDCK and LLC-PK1 cells were homogenized in a Potter using
a Teflon pestle, in a 1:4 volume of 22 mM sodium phosphate pH
7 with 250 m sucrose and 1 mtvi EDTA. The homogenate was
then centrifuged at 100 000 X g for one hour. GST activity was
measured with 1-chloro-2,4-dinitrobenzene as the substrate [38].
Effect of the GSH content on cytotoxicily
The effect of the GSH content on the cytotoxicity was measured
by the neutral red uptake after a pretreatment during 24 hours
with 1 mrvi OTC, 10 kM BSO or 100 /.tM BSO, followed by a 24
hours treatment with 1 mM OTC, 10 M BSO or 100 LM BSO in
the presence of the test compounds.
Statistics
The experiments were performed three times (except for
hPTC), using four or eight wells for each concentration of test
agent. EC5O values are presented as means SD. Means were
analyzed by the Student t-test. Statements of significance were
based on a P < 0.05 value.
Results
Cytotoxicity of the merculy compounds
Three types of kidney cells (LLC-PK1 and hPTC, both of
proximal tubular origin, and MDCK of distal tubular origin), liver
cells (Hep G2) and osteoblast cells (SAOS) were used to test the
toxicity of six different mercury compounds. Four cytotoxicity tests
were used: neutral red uptake, MTF conversion, thymidine incor-
poration and the total protein content. They reflect a transport
function at the level of the plasma membrane, a mitochondrial
function and cell proliferation.
Figure 1 shows a typical neutral red uptake profile for a cell line
(MDCK) and a primary culture of hPTC. Results for both cell
lines clearly indicate that two groups of mercury compounds could
be distinguished. PMA, EMT and MMC are one order of
magnitude more effective in interfering with the neutral red
uptake than MC, MN and MA.
EC5O values for the cytotoxicity tests are shown in Table 1.
Although each of the four tests chosen reflect a particular
function, no differences were found between the ECSO values for
the different tests. LLC-PK1 cells were in most cases more
susceptible to MC, MN and MA compared to the other cell lines.
Figure 2 shows the profiles of thymidine incorporation for
LLC-PK1 and MDCK. In MDCK cells low (2 to 50 j.LM) mercury
concentrations increased the thymidine incorporation (Fig. 2A).
Such a profile was not found for the other cell lines tested (Fig.
2B). Although thymidine incorporation did enhance drastically
for MC, MN, MA and PMA (up to 500%) in MDCK cells, no
equally enhanced protein content (up to 120%) could be found
for the same mercury concentrations indicating a nonspecific
thymidine incorporation. This was confirmed by the DNA content
measured in MDCK cells after 24 hours treatment with 30 M
MC. The DNA content was 978 100 g DNA/well, that is, 133%
of the control value (733 33 jtg DNA/well).
Uptake of the mercurials as measured by absorption spectrometty
Cellular mercury uptake was studied in MDCK or LLC-PK1
cells after 24 hours treatment. This study was limited to MC,
MMC, EMT and PMA, where MC represents the less toxic group
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Fig. 1. Concentration-dependent cytotoxicity of six mercury compounds
measured by the neutral red uptake inhibition. Symbols are: (0) MC; (0)
MN; (tx) MA; (•) MMC; (•) EMT; (A) PMA. Confluent cultures of
MDCK (A) or hPTC (B) were exposed to the compounds in culture
medium supplemented with 1% FCS for 24 hours. The percentage of
neutral red uptake was plotted against the log-molar concentration of
mercury. Values are the mean of 8 measurements SD.
and MMC the group with higher toxicity. EMT and PMAwere
included in the study because of their more complex chemical
structure compared to MC and MMC. A concentration of 1.5 .LM
was chosen because of its limited toxic effects measured in the
neutral red uptake and MTF conversion. The cellular mercury
content, after 24 hours incubation, was measured by the HPLC-
hydrid generation AAS (Table 2). In MDCK cells the uptake of
Hg was 10 times higher for MMC than for MC. For LLC-PK1 cells
the same concentration (1.5 LM) resulted in a comparable cellular
mercury content: 32.0 3.3 ng Hg/mg protein for MC and 76.9
2.2 ng Hg/mg protein for MMC. Uptake values for EMT and
PMA in MDCK cells were 237.3 69.7 and 270.8 75.7 ng
Hg/mg protein, respectively, and intermediate between the values
for MC and MMC.
To show the relation between cytotoxicity (EC5O) and cellular
uptake the MC/MMC ratio of the EC5O value and of the mercury
uptake were calculated (Table 3). The cytotoxicity of MMC
compared to MC was 5 to 8 times higher; this corresponds with a
10 times higher uptake of MMC in MDCK. The same relation was
Table 1. ECSO values for the neutral red uptake, MTF conversion,
thymidine incorporation and total protein content
Compound
Cell line
hPTC MDCK LLC-PK1 Hep G2 SAOS
Neutral red
uptake
MC 144.0 83.6 11.7 9.4 0.9 30.8 4.5 48.2 20.2
MN 159.0 58.0 6.6 9.9 2.6 33.0 5.6 54.2 24.0
MA 160.0 90.8 37.0 10.1 2.7 36.3 11.1 46.0 19.7
MMC 2.5 10.2 3.0 5.3 0.0 13.6 8.1 6.0 2.4
EMT 2.7 8.1 1.1 4.2 2.5 13.8 7.5 3.9 2.6
PMA 1.5 5.7 1.8 1.4 0.5 6.4 4.1 1.5 1.0
MIT conversion
MC 124.0 88.9 8.7 55.6 47.1
MN 128.0 88.4 5.7 34.0 48.7
MA 136.0 108.8 7.1 63.5 48.8
MMC 7.4 16.5 6.9 10.5 2.7
EMT 3.5 14.0 4.1 16.0 0.4
PMA 2.2 11.2 5.1 6.1 1.3
Thymidine
incorporation
MC — 88.4 7.8 47.3 29.0
MN — 87.5 10.1 57.0 32.0
MA — 100.3 10.0 30.2 27.9
MMC — 15.4 3.5 25.0 3.5
EMT — 12.2 3.6 19.1 1.5
PMA — 11.1 5.5 19.2 0.7
Protein content
MC — 61.9 8.9 37.7 28.5
MN — 64.3 11.5 48.3 36.7
MA — 81.1 9.4 25.5 30.7
MMC — 13.0 3.2 13.3 5.4
EMT — 11.7 3.7 13.0 2.0
PMA — 7.2 4.8 7.3 1.3
Cytotoxicity of six mercury compounds was measured in hPTC, MDCK,
LLC-PK1, Hep G2 and SAOS. Relative toxicity was established by the
determination of the EC5O value. This is the concentration (I.rM) of the
test compound inducing 50% reduction in the activity tested. Neutral red
uptake was at least performed three times for all the compounds and cell
lines except for hPTC. EC5O values for the neutral red uptake are
presented as the mean SD of three experiments. The ECSO values for the
other tests were the result of a single experiment.
found for LLC-PK1. For both MDCK and LLC-PK1 cells the
cytotoxicity was proportional to the mercury content.
Alteration of the GSH content in the cells
Measurements of the GSH content and glutathione S-trans-
ferase activities in the different cell lines revealed the following
steady-state GSH levels: MDCK, 21.2 5.8 big/mg protein;
LLC-PK1, 3.6 0.3 pg/mg protein; Hep G2, 6.6 3.3 .tg/mg
protein; SAOS, 5.9 1.5 xg/mg protein; and hPTC, 2.5 g/mg
protein. The glutathione S-transferase activity in MDCK and
LLC-PK1 was 303 32 nmol/min/mg protein and 72 10
nmol/min mg protein, respectively.
The effect of GSH on the toxicity of six mercury compounds was
studied after reduction of the endogeneous GSH content with
L-buthionine sulfoximine (BSO), a specific inhibitor of GSH
synthesis. Stimulation of the GSH content was also tried with
2-oxo-4-thiazolidine carboxylic acid (OTC), a specific substrate
for GSH synthesis. At 1 mrvi OTC a maximal elevation of the GSH
level of 20% in MDCK was found, whereas in the other cell types
no OTC effect could be observed. In preliminary experiments, the
influence of BSO and OTC on cell viability was measured. A
0'1 10 100
Concentration of mercury compound, M
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Cell line
MDCK LLC-PK1
MC 42.8 2.5 32,0 3.3
MMC 596.9 67.8 75.9 2.2
The results are presented as the mean so. They are the result of three
experiments.
Cel1 line
MDCK LLC-PKI
EC5O of MC/EC5O of MMC
Neutral red uptake 8.2 1.8
MTT conversion 5.4 1.1
Thymidine incorporation 5.7 2,2
Protein content 4.8 2.8
MC Hg uptake/MMC Hg uptake 0.1 0.4
at control conditions and in the presence of BSO or OTC in
MDCK, LLC-PK1, SAOS, Hep G2 and hPTC cells. Since previous
experiments (Table 1) showed striking comparable EC5O values in
the different tests, the influence of the GSH system on the toxicity
of mercury was only studied in the neutral red uptake.
0 5 10 15 20 25 30 Inhibition of the GSH synthesis with BSO was most pro-
nounced in MDCK and Hep G2 cells, resulting in a more
enhanced cytotoxicity in these cells compared to LLC-PK1, SAOS
and hPTC effects. BSO and OTC treatment significantly altered
the toxicity of MC, MA and MN. The lowered cytotoxicity after
treatment in the presence of OTC was rather surprising because
OTC did not enhance the GSH content. EC5O values for EMT
and PMA after OTC treatment were not significantly different
from the control values, whereas BSO treatment enhanced the
toxicity of EMT and PMA significantly. The effect of the OSH
content on the toxicity of MMC was rather limited, and this was
consistent throughout the whole study.
concentration of 400 .LM BSO had no influence on the viability of
MDCK and Hep 02 as measured by the neutral red uptake.
Substantial mortality was found at 100 xM BSO for LLC-PK1 and
SAOS cells, but 10 iM BSO had no effect on viability. A maximal
concentration of 2.1 mrvt OTC had no effect on the viability in each
of the four cell lines.
Optimal GSH suppression was found at a concentration of 100
LM BSO for MDCK (90% GSH suppressed), Hep G2 (70% GSH
suppressed) and hPTC (50% GSH suppressed). Since this con-
centration, however, was toxic for LLC-PK1 and SAOS cells, a
lower non-toxic concentration of 10 .LM BSO was used for these
cells. Under this condition, 50% of the GSH content was sup-
pressed in SAOS cells and 55% in LLC-PK1 cells. In optimal OTC
conditions (1 mM) we found a maximal elevation of the GSH level
of 20% in MDCK; in the other cell types no OTC effect could be
observed.
Influence of the GSH system on the toxicity of the mercury
compounds
Table 4 shows a comparison of the EC5O values for NR
obtained after a treatment with the different mercury compounds
A Table 2. Cellular mercury content (ng Hg/mg protein) measured by
atomic absorption spectrometry, after addition of 1.5 .rM MC and 1.5
ILM MMC to the cell culture medium during 24 hours
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Fig. 2. Thymidine incorporation measured after 24 hours treatment of
MDCK (A) and LLC-PK7 (B) cells with the six mercuty compounds in
culture medium with 1% FCS. Symbols are: (0) MC; (El) MN; (Li) MA;
(•) MMC; (U) EMT; (A) PMA. Values are the mean of 8 measurements
SD.
Table 3. MC/MMC EC5O ratio, and MC/MMC mercury uptake ratio in
MDCK and LLC-PK1 cells
40
20
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Concentration of mercury compound, M
Interaction of BSO and OTC with the mercury compounds
The influence of BSO on the cellular uptake of MC, MMC and
EMT in MDCK cells was measured by HPLC-hydrid generation
AAS. MC and EMT were both chosen because they showed an
enhanced cytotoxicity after GSH depletion with BSO, whereas
OTC lowered the toxicity of MC only. MMC was chosen because
its cytotoxicity was not clearly related to the GSH content. The
cells were pretreated with 100 jiM BSO in complete medium. The
medium was replaced after 24 hours by DMEM + 1% FCS
containing 100 jiM BSO and a sublethal concentration of 1.5 jiM
MC, 1.5 jiM MMC or 0.15 jiM EMT. The results were compared
with a control experiment using the same mercury concentrations
but without BSO. No significant differences in mercury uptake
were observed between the controls and the BSO treated cells,
suggesting that inhibition of the GSH synthesis plays a role in this
more pronounced toxicity (Table 5).
We further investigated the interaction of BSO and OTC with
the mercury compounds (MC and EMT) by the HPLC-hydrid
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Table 4. EC5O values for the neutral red uptake after treatment with
mercury at control conditions used and in the presence of BSO or OTC
Compound Control BSO Ri OTC R2
MDCK 100 psi 10% GSH 120% GSH
MC 174.0 23.0 6.83 0.16" 26 728.0 32.Oa 0.24
MN 132.0 48.9 3.10 0.30" 43 657.0 93.Oa 0.20
MA 123.2 33.5 5.50 018b 22 490.0 660b 0.25
MMC 18.6 1.5 4.71 0.25" 4 22.0 2.3" 0.85
EMT 14.8 4.5 0.97 007b 15 19.1 1.6= 0.77
PMA 9.7 1.5 0.22 0.08" 44 11.9 3.1= 0.82
LLC-PK, 10 psi 45% GSH 100% GSH
MC 15.1 2.1 2.24 1.29a 7 495.0 25.0" 0.03
MN 13.0 1.8 3.94 2.22" 3 447.0 110.0" 0.03
MA 14.5 2.4 3.14 0.48" 5 40.3 12.9" 0.36
MMC 5.4 0.26 5.57 1.23" 1 8.1 26d 0.67
EMT 4.3 0.62 1.80 0.29" 2 5.2 0.7" 0.83
PMA 4.5 0.26 2.86 0.66" 2 6.7 1.0" 0.67
Hep G2 100 psi 30% GSH 100% GSH
MC 64.6 14.2 9.38 276b 7 650.0 27.0" 0.10
MN 81.6 13.3 5.23 0.81" 16 680.0 57.0" 0.12
MA 68.3 15.9 9.71 3.11" 7 299.0 20.0" 0.23
MMC 24.4 3.2 7.18 1.85" 3 34.0 3.1" 0.72
EMT 21.7 0.6 2.67 0.70" 8 24.4 6.4" 0.89
PMA 9.8 3.7 0.90 0.23" 11 15.9 8.9" 0.62
SAOS 10 psi 50% GSH 100% GSH
MC 64.8 8.5 15.00 4.20" 4 506.0 128.0" 0.13
MN 63.1 12.5 16.90 270b 4 544.0 38.0" 0.12
MA 51.1 7.4 20.00 070b 3 209.0 38.0" 0.24
MMC 4.9 1.0 2.85 1.17" 2 5.6 2.7" 0.88
EMT 3.6 1.0 2.25 1.28" 2 4.5 29.9" 0.80
PMA 0.9 0.3 0.41 0.22" 2 0.9 0.1" 1.00
PTC 100 psi 50% GSH
MC 173.0 69.5 2 581.0 0.12
MN 138.0 41.4 3 452.0 0.09
MA 183.0 83.8 2 276.0 0.30
MMC 9.3 3.3 3 7.3 1.27
EMT 5.1 2.5 2 5.0 1.02
PMA 3.7 0.6 6 5.0 0.74
Cells were pretreated for 24 hr with culture medium + 10% FCS
without (control) or with BSO (10 to 100 pM) or OTC (1 mM). After 24 hr
this medium was replaced with fresh medium + 1% FCS with mercury and
without (control) or with BSO (10 to 100 pM) or OTC (1 mM) for another
24 hr. Cytotoxicity of six mercury compounds was established by the
neutral red uptake test. EC5O values (pM) are presented as the mean SD
and are the result of at least three experiments. Ri = control/BSO ratio
shows an enhanced mercury cytotoxicity; R2 = control/OTC ratio indi-
cates a lowered mercury cytotoxicity.
N150 values of BSO or OTC are significantly different from the control
value when: "P <0.001, bp <0.01, "P <0.02 and "P <0.05
not significantly different
generation AAS [35] to check whether an aspecific extracellular
binding with both compounds could influence the uptake. In
buffered solutions no interaction between BSO and the mercury
compounds was observed. In contrast, OTC formed complexes
with MC but not with EMT, Experiments comparing the cytotox-
icity of mercury in control and in OTC (24 hr) pretreated cells
supported the interaction hypothesis. Indeed, when MDCK cells
were submitted to a two hour treatment with MC, MMC and
EMT under three different conditions (Table 6), no significant
differences were found between the control and +OTC/—OTC
conditions for MC and MMC, but the +OTC/+OTC conditions
were significantly less toxic. No differences were observed be-
tween controls, +OTCI—OTC and +OTC/+OTC for EMT.
Discussion
The toxicity of six mercury compounds was investigated on
kidney cells (MDCK, LLC-PK1 and hPTC). To evaluate the organ
Table 5. Effect of BSO on mercury uptake
Mercury uptake ng Hg/mg protein
Control BSO P
MC 97.09 12.20 68.00 8.16 NS
MMC 743.16 262.56 364.80 80.99 NS
EMT 176.33 60.13 62.04 3.60 NS
The cellular uptake of MC (1.5 pM), MMC (1.5 pM) and EMT (0.15
pM) in MDCK cells was measured by atomic absorption spectrometry
after a 24 hour treatment without (control) or with 100 pal BSO. Results
are presented as the mean so and are the result of three experiments.
Means were analyzed by Student's t-test. Statements of significance were
based on a P value less than 0.05.
NS is not significantly different.
Table 6. Interaction of OTC with mercury in MDCK cells
Compound Control +OTC/-OTC R, +OTC/+OTC R2
MC 147.0 9.0 167.0 2.0" 0.88 826.0 35.0" 0.18
MMC 16.9 2.0 17.9 0.4" 0.94 87.5 70b 0.36
EMT 82.8 8.0 83.4 0.2" 0.99 46.3 8.1c 1.49
MDCK cells were pretreated during 24 hours with DMEM supple-
mented with 10% FCS without (control) or with 1 mai OTC. Cells were
then treated for 2 hours with MC, MMC or EMT in the absence
(+OTC/—OTC) or in presence (+ OTC/+OTC) of OTC. Cytotoxicity was
measured by the neutral red uptake. The cytotoxicity was established by
the EC5O value (pM) presented as the mean SD, and is the result of at
least three experiments. R1 = control/(+OTC/—OTC) ratio, R2 =
control/(+OTC/+OTC) ratio.
ap < 0.01
bp <0.05
not significantly different
specific reaction of the kidney cells, the same compounds were
also investigated on liver (Hep G2) and osteoblast (SAOS) cells.
Cytotoxicity was measured in four different tests: neutral red
uptake, MTT conversion, thymidine incorporation and the total
protein content. They reflect a transport function at the level of
the membrane, a mitochondrial function and cell proliferation,
respectively. Relative toxicity was established by the determina-
tion of the EC5O value for the different tests. Although each of the
four chosen tests reflect a particular function, no major differ-
ences between the EC5O values for the different tests were found.
Regarding the toxicity of the different mercury compounds, we
could distinguish two groups which were apparent in MDCK,
SAOS and hPTC for all the tests performed. EMT, PMA and
MMC were one order of magnitude more toxic than MC, MN and
MA. Aleo, Taub and Kostyniak [14] reported 50% inhibition of
trypan blue exclusion in rabbit proximal tubular cells at concen-
trations of MC (32.2 pM) or MMC (6.1 pM) comparable to our
50% inhibition concentrations of MC and MMC measured for the
different tests in MDCK, Hep G2 and SAOS. hPTC were less
sensitive to MC, MN and MA. A comparative toxicity study of
PMA and MA in rat kidney slices showed, as for our results, a
higher toxicity of PMA. The authors suggested that a different
intracellular distribution could be responsible for the difference in
toxicity [39]. A comparative study of mercuric chloride, ethyl
mercuric chloride, methyl mercuric chloride and phenyl mercuric
chloride toxicity on BGIF epithelioid cells showed that mercuric
chloride is one order of magnitude less toxic than the other
compounds [40]. These results are in agreement with our results.
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The cellular uptake of the mercury compounds was studied in
order to explain the observed differences in toxicity. A MC or
MMC treatment of 1.5 xM was given to both MDCK and
LLC-PK1 cells. The MMC uptake was 10 times higher than the
MC uptake in MDCK cells as measured by atomic absorption
spectrometry. This higher uptake was in agreement with the
higher toxicity of MMC (4 to 8 times more toxic than MC)
measured in the cytotoxicity assays. Also in LLC-PK1 cells the
higher toxicity of MMC compared to MC matched the two times
higher cellular uptake of MMC compared to MC. Cellular
mercury toxicity in MDBK cells was also directly related to the
ability of the cells to accumulate mercury [41]. Lipophilicity plays
an important role in the uptake and biological action of mercu-
rials; MMC is more lipophilic than MC as assessed by the
octanol/water distribution of mercury compounds [42]. The lipid-
soluble form of MMC might enter by diffusion through the
membrane, while the ionic form of MC could enter through
discrete ion channels [43]. This results in a lower uptake of MC.
Lower toxicity of MC compared to MMC could also be partially
explained by the fact that mercury administration could induce
metallothionein (MT) synthesis in kidneys, as supported by the
observation of Piotrowski et al [44]. It was shown that organic
mercury, such as MMC, did not bind to MT [45], while inorganic
mercury did [44].
Inorganic mercury accumulates mainly in the renal cortex and
the outer stripe of the outer medulla, especially in the proximal
straight tubules. Negligible amounts of inorganic mercury were
detected in the distal segments of the nephron and collecting duct
[2, 3, 46]. Therefore, the proximal tubular segment is very
important in toxicological studies. Studies have mostly been
carried out with non-human cells such as MDCK (distal tubular
origin) and LLC-PK1 (proximal tubular origin) cells. Apart from
the obvious species differences, those cell lines generally lack
specific biochemical and physiological functions that play an
important role in certain forms of target-cell toxicity.
Studies with primary cultures of human proximal tubules have
the advantage that the cells still possess their specific features [30].
The kidney cells, except LLC-PK1, showed no higher mercury
sensitivity than Hep G2 and SAOS. hPTC cells, still possessing
specific features, reveal lower sensitivity to MC, MA and MN. The
toxicity of MC, MN and MA is much higher (5 to 10 times) in
LLC-PK1 cells than in the other cell lines investigated, although
the cellular uptake of MC by LLC-PK1 cells (32.0 3.3 ng Hg/mg
protein) is similar to the uptake measured in MDCK cells (42.8
2.5 ng Hg/mg protein). Higher toxicity could be related to the
lower GSH content and glutathione S-transferase activities mea-
sured in LLC-PK1 cells compared to MDCK cells.
Thymidine incorporation in MDCK cells was stimulated up to
500% after treatment with low (50 M) MC, MN, MA or PMA
concentrations, whereas MMC and EMT did not result in an
enhanced thymidine incorporation. MC and MN slightly in-
creased the thymidine incorporation in LLC-PK1. This nonspe-
cific "thymidine incorporation", that is, the increase at low
mercury concentrations, has no relation with the number of cells,
as could be concluded from microscopic observations and from
DNA measurements performed on cells treated in the same
conditions. This is also confirmed by the corresponding EC5O
values at higher concentrations which agree very well with those
obtained in the NR and MTT assay. Enhanced thymidine incor-
poration was measured in MDBK (bovine kidney cell line)
following a 24 hour incubation with 5 MC [13] and after acute
incubation of astroglial cells in 1 nM MC [47]. The physiological or
toxicological significance of the stimulation of thymidine incorpo-
ration after incubating the cultures at low mercury concentrations
is not fully understood [47]. We postulate that the mercury-
induced weakened plasma membrane results in an enhanced
cellular thymidine uptake. This hypothesis is supported by the
studies of Ochi, Takahashi and Ohsawa [48] and Bracken and
Sharma [13]. The stimulation of thymidine incorporation could
furthermore be the result of an altered thymidine kinase activity
[49] or of a selective enhancement of intracellular thymidine
transport caused by MC [13]. The authors also observed that
MMC in contrast to MC did not stimulate the incorporation in
mouse glioma cells [49], which was also found in our study.
Aleo, Taub and Kostyniak [14] suggested that GSH may be
involved in the protection of rabbit PTC cells against MC insult.
GSH plays an important role in the detoxification of potentially
toxic compounds by its binding with them. This conjugation is
catalyzed by glutathione 5-transferase. In the present study the
cytotoxic effect of six mercury compounds was studied in five cell
lines after alteration of the GSH content with BSO or OTC.
BSO treatment enhanced the toxicity of all compounds. How-
ever, for MMC the situation is less clear. MDCK cells were more
sensitive to mercury after BSO treatment than the other cells.
This effect could possibly be caused by a higher maximal GSH
depletion in MDCK (90%) compared to LLC-PK1 (45%), hPTC
(50%) and SAOS (50%). We assume that the limited depletion in
hPTC, LLC-PK1 and SAOS may be related to the low basal
steady-state GSH level in these particular cell lines. In LLC-PK1
and SAOS the weaker GSH depletion can be attributed to the
lower BSO concentration (10 LM). Enhancement of inorganic
mercury (MC) toxicity was also found by Liu et al [50] and
Guillermina, Adriana and Monica [181 after treatment with BSO
or DEM. The influence of the GSH system on the toxicity of
MMC is not clear. GSH protects cells derived from the nervous
system against MMC insult [17, 51], although in rabbit proximal
tubule cells MMC binds preferentially to the acid-insoluble
protein sulihydryl groups rather than to GSH or metallothioneins
[14]. MMC treatment resulted furthermore in a concentration-
dependent disassembly of microtubules, but microtubule damage
could not be enhanced by depletion of GSH with BSO [22].
Although we found a limited or no effect of OTC on the GSH
content, the toxicity of MC, MN and MA diminished up to 34
times. Nearly no effect of OTC on the toxicity of MMC, EMT and
PMA was found. This discrepancy is explained by the observation
that OTC interacts with MC, but not with EMT. Since OTC had
no effect on the GSH content, the lower toxicity of MC, MN and
MA could be explained by extracellular interaction of OTC with
the mercury compounds before they interact with the target cells.
Protection against inorganic mercury toxicity could be obtained
after GSH treatment of the segments of the proximal tubule [52]
and after GSH monoethyl ester pretreatment in rats [19]. Neither
GSH or GSH monoethylester could enhance the GSH content in
our cells (results not shown).
In the present study we showed that the mercury compounds
can be divided in two groups regarding their toxicity and uptake.
Enhanced cytotoxicity caused by BSO treatment proved an in-
volvement of GSH in the detoxification of mercury. OTC de-
creased the cytotoxicity, not by an enhanced GSH content, but
rather by an extracellular interaction of OTC with mercury. No
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major differences concerning the cytotoxicity were observed be-
tween the different tests and cell lines used. hPTC, which still
possess proximal tubular features, seemed to be no more vulner-
able to mercury than the other cell lines. Established cell lines
were revealed as good tools for a comprehensive toxicity study.
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Appendix. Abbreviations
AAS = alternatives to laboratoiy animals, BSO = L-buthionine sulfoxi-
mine, DEM = diethylmaleate, DMEM = Dulbecco's modified Eagle's
medium, EMT sodium ethylmercurithiosalicylate, FCS = fetal calf
serum, GSH = glutathione, GST = glutathione S-transferase, HBSS =
Hank's balanced salt solution, hPTC = human proximal tubular cells,
M199 = medium 199, MA = mercury acetate, MC = mercury chloride,MMC = methyl mercury chloride, MN = mercury nitrate, MT =
metallothionein, Mn' 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetra-
zolium bromide, NR = neutral red, NUT MIX = Nutrient Mix, PBS =
phosphate buffered saline, OTC = 2-oxo-4-thiazolidine carboxylic acid,
PMA = phenylmercury acetate.
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